Clinical Trials

  • Clinical Trials
  • Nomination of a clinical candidate and subsequent conduct of toxicology studies to support a first-in-human (FIH) clinical trial is an exciting milestone for sponsors! While many are highly experienced drug discovery professionals, some may have limited, or even no experience, in early clinical development, including the critical toxicology studies required to successfully support a FIH trial.

    The complexities of active pharmaceutical ingredient (API) formulation, product testing, and documentation requirements can hinder the speed at which a promising drug candidate progresses to and through clinical trials.

    :root { --primary-green: #00685e; --button-green: #009867; --dark-green: #004d40; --light-green: #e0f2f1; --text-dark: #333; --text-light: #fff; --light-purple: #e4ebf5; --accent-green: #4db6ac; } .container { max-width: 1040px; margin: 0 auto; background-color: #fff; box-shadow: 0 0 20px rgba(0, 0, 0, 0.1); } .text-intro { text-align: center; font-size: 1.2em; padding: 0 4rem 0 4rem; } /* Header */ /* Header */ header { pad

    Drug-drug interactions (DDIs) can pose significant safety risks, particularly in cardiovascular therapies, where patients are often on multiple medications. By analyzing these interactions early, we can help your studies stay on track and avoid potential regulatory roadblocks.

    Case Study—Accelerating Recruitment in Renal Impairment Trials: Leveraging Specialized External Sites

    STAT: Responsible AI Frees Scientists to Focus on Science

    CLINDMO: Where Clinical Innovation Meets Manufacturing Excellence

    Spray-dried dispersions (SDDs) are an effective method to improve solubility and bioavailability of your active pharmaceutical ingredient (API) in early-phase drug development. The spray drying process involves converting a liquid into a dry powder, with the resulting SDDs benefiting from improved characteristics for further developments. Spray drying can also be combined with nanomilling to further improve the bioavailability, and for flexible downstream processing. 

    In Issue 46 of The Altascientist, explore: 

    • how SDDs improve efficiency of early-phase drug development
    • applications and benefits of spray drying in early-phase drug manufacturing
    • advances in spray drying technology for pharmaceutical development
    • the use of spray dry technology in early-phase development of proteins and peptides
    • key considerations for the development of spray-dried pharmaceuticals
     

     

    Clinical Trials Without Boundaries: Multi-Site Solutions at Altasciences

    Subscribe to Clinical Trials